Novartis succeeds where Alexion failed, coming up with a win for a prized asset in a rare kidney disorder
Three months after Alexion stumbled, Novartis declared another Phase II success for a drug it hopes can carve out significant new indications and potentially compete with Soliris.
Novartis said today that iptacopan, also known as LNP023, successfully cut proteinuria — elevated protein levels in urine, an indicator of kidney inflammation — in half across 12 patients with the rare kidney disease C3G (P=0.0005). That’s the same disease where, in July, one of the two big drugs Alexion picked up in their $930 million Achillion buyout flopped.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.